Boston Scientific Corporation $BSX Shares Sold by Robeco Schweiz AG

Robeco Schweiz AG cut its holdings in Boston Scientific Corporation (NYSE:BSX) by 29.2% in the 3rd quarter, according to its most recent 13F filing with the SEC. The firm owned 58,083 shares of the medical equipment provider’s stock after selling 23,999 shares during the period. Robeco Schweiz AG’s holdings in Boston Scientific were worth $5,671,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also recently bought and sold shares of the business. Norges Bank bought a new position in shares of Boston Scientific during the second quarter valued at approximately $2,089,937,000. Edgewood Management LLC bought a new position in Boston Scientific during the 2nd quarter worth $746,655,000. Parnassus Investments LLC increased its position in Boston Scientific by 42,978.9% in the third quarter. Parnassus Investments LLC now owns 6,884,440 shares of the medical equipment provider’s stock worth $672,128,000 after buying an additional 6,868,459 shares during the period. Bessemer Group Inc. lifted its stake in Boston Scientific by 14,391.8% in the second quarter. Bessemer Group Inc. now owns 2,919,801 shares of the medical equipment provider’s stock valued at $313,618,000 after buying an additional 2,899,653 shares during the last quarter. Finally, Vanguard Group Inc. grew its position in shares of Boston Scientific by 1.9% during the second quarter. Vanguard Group Inc. now owns 137,134,110 shares of the medical equipment provider’s stock worth $14,729,575,000 after acquiring an additional 2,545,381 shares during the last quarter. Institutional investors and hedge funds own 89.07% of the company’s stock.

Insider Transactions at Boston Scientific

In related news, Director Ellen M. Zane sold 12,891 shares of the business’s stock in a transaction that occurred on Thursday, November 6th. The shares were sold at an average price of $98.28, for a total value of $1,266,927.48. Following the sale, the director directly owned 24,134 shares in the company, valued at $2,371,889.52. The trade was a 34.82% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, EVP Arthur C. Butcher sold 17,313 shares of the stock in a transaction that occurred on Monday, December 1st. The shares were sold at an average price of $101.55, for a total transaction of $1,758,135.15. Following the sale, the executive vice president directly owned 23,600 shares of the company’s stock, valued at approximately $2,396,580. This represents a 42.32% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 93,095 shares of company stock valued at $9,305,450 in the last quarter. Insiders own 0.50% of the company’s stock.

More Boston Scientific News

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: FDA clearance for the Farapoint PFA catheter expands BSX’s electrophysiology portfolio and supports procedure-driven recurring revenue; regulatory win should accelerate commercial roll‑out in atrial fibrillation ablation. Article Title
• Positive Sentiment: Agreement to acquire Valencia Technologies broadens BSX’s pelvic/uroLOGY offering for urinary incontinence and overactive bladder — gives exposure to a high-growth segment and supports the company’s stated pelvic-health strategy. (Official release) Article Title
• Positive Sentiment: J.P. Morgan coverage/notes highlight expectations for strong PFA performance in 2026 and beyond, reinforcing growth prospects for BSX’s higher‑margin electrophysiology portfolio. Article Title
• Positive Sentiment: Bank of America (analyst Travis Steed) reaffirmed a Buy rating and a $120 price target, citing strategic pelvic‑health expansion and the Valencia deal as upside drivers. Article Title
• Positive Sentiment: Sector write‑ups note BSX is benefiting from favorable product‑mix shifts toward higher‑margin devices, supporting margin expansion and durable revenue growth. Article Title
• Neutral Sentiment: Management’s JP Morgan conference presentation/transcript provides updated strategic context and reinforcement of guidance, useful for modeling but not a discrete catalyst by itself. Article Title
• Negative Sentiment: Short‑term sell pressure: some coverage noted the stock fell despite a strong market day and higher volume — suggesting profit‑taking, rotation away from richly valued medtech names (BSX’s trailing P/E is elevated) may be weighing on the share price. Article Title

Analyst Ratings Changes

BSX has been the topic of several recent research reports. Wall Street Zen downgraded shares of Boston Scientific from a “buy” rating to a “hold” rating in a research report on Saturday, December 20th. Weiss Ratings reaffirmed a “buy (b-)” rating on shares of Boston Scientific in a report on Wednesday, October 8th. Cowen reissued a “buy” rating on shares of Boston Scientific in a report on Thursday, December 11th. Royal Bank Of Canada raised their target price on Boston Scientific from $125.00 to $130.00 and gave the company an “outperform” rating in a research report on Wednesday, December 17th. Finally, Truist Financial reduced their price target on Boston Scientific from $130.00 to $120.00 and set a “buy” rating for the company in a research report on Thursday, December 18th. Two equities research analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating and two have assigned a Hold rating to the stock. Based on data from MarketBeat, Boston Scientific currently has an average rating of “Buy” and an average price target of $125.21.

Boston Scientific Stock Performance

BSX opened at $94.02 on Wednesday. Boston Scientific Corporation has a 1-year low of $85.98 and a 1-year high of $109.50. The company has a market capitalization of $139.37 billion, a price-to-earnings ratio of 50.28, a price-to-earnings-growth ratio of 1.69 and a beta of 0.67. The business has a 50 day moving average price of $97.43 and a two-hundred day moving average price of $100.58. The company has a debt-to-equity ratio of 0.47, a current ratio of 1.51 and a quick ratio of 0.96.

Boston Scientific (NYSE:BSX) last announced its quarterly earnings data on Wednesday, October 22nd. The medical equipment provider reported $0.75 earnings per share for the quarter, beating the consensus estimate of $0.71 by $0.04. Boston Scientific had a return on equity of 19.46% and a net margin of 14.43%.The business had revenue of $5.07 billion during the quarter, compared to analyst estimates of $4.97 billion. During the same quarter in the prior year, the firm posted $0.63 earnings per share. The company’s revenue was up 20.3% on a year-over-year basis. Boston Scientific has set its FY 2025 guidance at 3.020-3.040 EPS and its Q4 2025 guidance at 0.770-0.790 EPS. Research analysts predict that Boston Scientific Corporation will post 2.85 EPS for the current fiscal year.

About Boston Scientific

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.